RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM
Clinical trials for RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat HER2+ cancers
Disease control Recruiting nowThis study compares the drug neratinib alone versus neratinib plus palbociclib in people with HER2-positive gynecologic and other solid tumors (excluding breast cancer). Both drugs block signals that make cancer cells grow. The goal is to see if the combination shrinks tumors or …
Matched conditions: RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:34 UTC
-
Genetic matchmaking for cancer: ComboMATCH trial aims to personalize therapy
Knowledge-focused Recruiting nowThis study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…
Matched conditions: RECURRENT MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 11:47 UTC